178 related articles for article (PubMed ID: 33783343)
21. A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs.
Alla VM; Agrawal V; DeNazareth A; Mohiuddin S; Ravilla S; Rendell M
Drugs; 2013 Jul; 73(10):1025-54. PubMed ID: 23754124
[TBL] [Abstract][Full Text] [Related]
22. Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.
Giugliano RP; Keech A; Murphy SA; Huber K; Tokgozoglu SL; Lewis BS; Ferreira J; Pineda AL; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
JAMA Cardiol; 2017 Dec; 2(12):1385-1391. PubMed ID: 29117276
[TBL] [Abstract][Full Text] [Related]
23. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
24. Statin combination therapy and cardiovascular risk reduction.
Toth PP; Farnier M; Tomassini JE; Foody JM; Tershakovec AM
Future Cardiol; 2016 May; 12(3):289-315. PubMed ID: 27079178
[TBL] [Abstract][Full Text] [Related]
25. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials.
Koskinas KC; Siontis GCM; Piccolo R; Mavridis D; Räber L; Mach F; Windecker S
Eur Heart J; 2018 Apr; 39(14):1172-1180. PubMed ID: 29069377
[TBL] [Abstract][Full Text] [Related]
26. Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.
Foody JM; Toth PP; Tomassini JE; Sajjan S; Ramey DR; Neff D; Tershakovec AM; Hu H; Tunceli K
Vasc Health Risk Manag; 2013; 9():719-27. PubMed ID: 24265554
[TBL] [Abstract][Full Text] [Related]
27. PCSK9 inhibitors--past, present and future.
Reiner Ž
Expert Opin Drug Metab Toxicol; 2015; 11(10):1517-21. PubMed ID: 26329686
[TBL] [Abstract][Full Text] [Related]
28. Very low LDL-C levels may safely provide additional clinical cardiovascular benefit: the evidence to date.
McCormack T; Dent R; Blagden M
Int J Clin Pract; 2016 Nov; 70(11):886-897. PubMed ID: 27739167
[TBL] [Abstract][Full Text] [Related]
29. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety.
Hou R; Goldberg AC
Endocrinol Metab Clin North Am; 2009 Mar; 38(1):79-97. PubMed ID: 19217513
[TBL] [Abstract][Full Text] [Related]
30. Unmet Needs in LDL-C Lowering: When Statins Won't Do!
Krähenbühl S; Pavik-Mezzour I; von Eckardstein A
Drugs; 2016 Aug; 76(12):1175-90. PubMed ID: 27456066
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial.
Moriarty PM; Thompson PD; Cannon CP; Guyton JR; Bergeron J; Zieve FJ; Bruckert E; Jacobson TA; Kopecky SL; Baccara-Dinet MT; Du Y; Pordy R; Gipe DA;
J Clin Lipidol; 2015; 9(6):758-769. PubMed ID: 26687696
[TBL] [Abstract][Full Text] [Related]
32. Management of statin-intolerant high-risk patients.
Tziomalos K; Athyros VG; Karagiannis A; Mikhailidis DP
Curr Vasc Pharmacol; 2010 Sep; 8(5):632-7. PubMed ID: 20507273
[TBL] [Abstract][Full Text] [Related]
33. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.
Sullivan D; Olsson AG; Scott R; Kim JB; Xue A; Gebski V; Wasserman SM; Stein EA
JAMA; 2012 Dec; 308(23):2497-506. PubMed ID: 23128163
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial.
Cannon CP; Cariou B; Blom D; McKenney JM; Lorenzato C; Pordy R; Chaudhari U; Colhoun HM;
Eur Heart J; 2015 May; 36(19):1186-94. PubMed ID: 25687353
[TBL] [Abstract][Full Text] [Related]
35. Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy.
Jetty V; Glueck CJ; Lee K; Goldenberg N; Prince M; Kumar A; Goldenberg M; Anand I; Wang P
Vasc Health Risk Manag; 2017; 13():247-253. PubMed ID: 28740397
[TBL] [Abstract][Full Text] [Related]
36. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
Sabatine MS; Giugliano RP; Keech AC; Honarpour N; Wiviott SD; Murphy SA; Kuder JF; Wang H; Liu T; Wasserman SM; Sever PS; Pedersen TR;
N Engl J Med; 2017 May; 376(18):1713-1722. PubMed ID: 28304224
[TBL] [Abstract][Full Text] [Related]
37. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial.
Fleg JL; Mete M; Howard BV; Umans JG; Roman MJ; Ratner RE; Silverman A; Galloway JM; Henderson JA; Weir MR; Wilson C; Stylianou M; Howard WJ
J Am Coll Cardiol; 2008 Dec; 52(25):2198-205. PubMed ID: 19095139
[TBL] [Abstract][Full Text] [Related]
38. Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk.
Soran H; Adam S; Durrington PN
Atherosclerosis; 2018 Nov; 278():135-142. PubMed ID: 30273874
[TBL] [Abstract][Full Text] [Related]
39. Management of patients with statin intolerance.
Fischer S; Julius U
Atheroscler Suppl; 2017 Nov; 30():33-37. PubMed ID: 29096858
[TBL] [Abstract][Full Text] [Related]
40. Lipids: a personal view of the past decade.
Katsiki N; Mikhailidis DP
Hormones (Athens); 2018 Dec; 17(4):461-478. PubMed ID: 30229482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]